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A B S T R A C T
Niemann Pick type C (NPC) disease is a progressive lysosomal storage disorder caused by mutations in genes
encoding NPC1/NPC2 proteins, characterized by neurological defects, hepatosplenomegaly and premature
death. While the primary biochemical feature of NPC disease is the intracellular accumulation of cholesterol and
gangliosides, predominantly in endolysosomes, mitochondrial cholesterol accumulation has also been reported.
As accumulation of cholesterol in mitochondria is known to impair the transport of GSH into mitochondria,
resulting in mitochondrial GSH (mGSH) depletion, we investigated the impact of mGSH recovery in NPC
disease. We show that GSH ethyl ester (GSH-EE), but not N-acetylcysteine (NAC), restored the mGSH pool in
liver and brain of Npc1-/- mice and in ﬁbroblasts from NPC patients, while both GSH-EE and NAC increased
total GSH levels. GSH-EE but not NAC increased the median survival and maximal life span of Npc1-/- mice.
Moreover, intraperitoneal therapy with GSH-EE protected against oxidative stress and oxidant-induced cell
death, restored calbindin levels in cerebellar Purkinje cells and reversed locomotor impairment in Npc1-/-mice.
High-resolution respirometry analyses revealed that GSH-EE improved oxidative phosphorylation, coupled
respiration and maximal electron transfer in cerebellum of Npc1-/-mice. Lipidomic analyses showed that GSH-
EE treatment had not eﬀect in the proﬁle of most sphingolipids in liver and brain, except for some particular
species in brain of Npc1-/- mice. These ﬁndings indicate that the speciﬁc replenishment of mGSH may be a
potential promising therapy for NPC disease, worth exploring alone or in combination with other options.
1. Introduction
Niemann-Pick type C (NPC) disease is an inherited lysosomal
storage disorder that results in neurodegeneration, liver disease and
premature death [1,2]. The juveline and most common form of the
disease presents with progressive learning defects and ataxia and is
typically diagnosed between 6 and 15 years of age. Mutations in genes
encoding NPC1 and NPC2 proteins are causally linked to the pathology.
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Speciﬁcally, NPC1 mutations account for 95% of cases but also
alterations in NPC2 gene have been found [2,4]. NPC1 is a transmem-
brane protein that binds cholesterol in its luminal N-terminal domain
to allow its export, while NPC2 resides in the lysosomal lumen and
transfers cholesterol to NPC1 [5]. NPC1 deﬁciency in mice reproduces
many of the deﬁcits seen in NPC patients, including neurological
defects and ataxia by 6–7 weeks of age and reduces the maximal life
span to about 10–12 weeks [2,4]. Loss of function of NPC1 causes an
accumulation of free cholesterol in lysosomes and late endosomes
[3,4], thereby altering intracellular transport of cholesterol.
Accumulation of glycosphingolipids, especially GM2 and GM3 gang-
liosides, has been reported in brain of mouse models and patients [6].
NPC disease in patients and Npc1-/- mice is also characterized by
abnormal mitochondrial function and subsequent oxidative stress [7–
11]. However, the contribution of these observations to NPC disease is
not well understood. For instance, treatment with antioxidants such as
N-acetylcystetine (NAC), vitamin E or vitamin C, has shown little
impact in modifying NPC pathology, exerting a modest eﬀect (5–10%)
in the extension of life span in Npc1-/- mice [7,12,13].
Impaired egress and subsequent accumulation of cholesterol in
endolysosomes is the primary consequence of defective NPC1 function
and is considered a major pathogenic mechanism of NPC disease [2,4].
Moreover, increased levels of cholesterol in mitochondria from liver
and brain of Npc1-/-mice have been reported as well as [10,14,15] but
the role of this event in NPC disease has not been explored. Moreover,
mitochondrial cholesterol accumulation is known to decrease mito-
chondrial GSH (mGSH) stores by impairing cytosolic GSH transport
into mitochondria [16,17]. Therefore, our aim was to address the
impact of mGSH replenishment in Npc1-/- mice and ﬁbroblasts from
patients with NPC disease on the susceptibility to oxidant-induced cell
death and NPC pathology. We show that GSH ethyl ester (GSH-EE)
restores the mGSH pool and this event confers resistance to oxidative
stress and cell death, improves cerebellar mitochondrial function and
NPC pathology with a signiﬁcant increase in the median survival and
maximal life span of Npc1-/- mice. These ﬁndings reveal a key role of
mGSH depletion in the progression of this lysosomal disorder and
suggest that GSH-EE may be a promising approach for the treatment of
NPC disease worth of exploring alone or in combination with existing
options.
2. Materials and methods
2.1. Npc1-/- mice and ﬁbroblasts from patients with NPC disease
Npc1-/- mice (NPC1NIH, BALB/cJ strain) were obtained from The
Jackson Laboratories. At the time of weaning (21 days), mice were
genetically identiﬁed by PCR using DNA prepared from tail-tips and
following the genotyping protocols provided by the supplier. All
procedures involving animals and their care were approved by the
Ethics Committee of the University of Barcelona and were conducted in
accordance with institutional guidelines in compliance with national
and international laws and policies.
Cultured human skin ﬁbroblasts from control individuals (HSF;
GM5659D) and patients with NPC disease obtained from the
Laboratoire de Biochimie Metabolique, Institut Federatif de Biologie
(CHU Toulouse, France) and from Coriell Institute for Medical
Research (GM03123, NJ, USA) were grown at 37 °C in 5% CO2.
DMEM (Gibco) culture medium was supplemented with 10% fetal
bovine serum (FBS, Gibco, 10-270-106) and 10.000 U/mL Penicillin-
Streptomycin (Gibco, 15140-122).
2.2. In vitro and in vivo treatments
Primary mouse hepatocytes were isolated as described in
Supplementary Methods section. Hepatocytes and ﬁbroblasts from
NPC patients were pretreated with GSH-EE (5 mM) or N-acetylcys-
teine (NAC, 10 mM) and then treated with hydrogen peroxide (H2O2,
1 mM) (Sigma) to evaluate cell viability. In addition, 7-days old
Npc1-/- mice were treated with 1.25 mmol/kg GSH-EE (Sigma, St.
Louis, MO), 2.5 mmol/Kg NAC intraperioteneally (i.p.) or vehicle
(saline) every 12 h for 6 weeks to measure mGSH and total GSH
levels. For survival studies, 7-days old Npc1-/- mice were treated with
GSH-EE, NAC or vehicle every 12 h measuring body weight weekly
until demise.
2.3. Cell viability assays
Cell viability was performed based on trypan blue exclusion, double
staining with Hoechst 33258 as described previously [18] or by the
release of Glutathione-S-Transferase as detailed in Supplemental
materials and methods.
2.4. Motor coordination testing
All behavioral tests were conducted during the light cycle phase in
an enclosed behavior room. Same animals were used for two motor
tests, hanging test and beam transversal test, and results were
evaluated and analyzed by an investigator blinded to the groups as
described [19]. Brieﬂy, hanging test was used to assess neuromuscular
and locomotor development. Mice were placed on an iron wire and had
to suspend their body weight with their forelimbs to avoid falling and to
aid in progression around the rod. The latency to fall down and the
ability to grip the wire was scored as follows: 0, mice fall immediately;
1, grips the wire with forelimbs; 2, grips the wire with forepaws and
tries to support itself with its hind paws; 3, grips the wire with 3 or 4
paws; 4, grips the wire with 4 paws and twists its tail around the wire;
5, grips the wire with 4 paws, twists its tail around the wire and moves
to the pole. The maximum time permitted was 60 s. Beam transversal
test allows the quantiﬁcation of motor deﬁcit by measuring the time
spent to arrive to the platform once all four paws of the animals are in
contact with the beam (escape latency, EL), the time spent before
falling (tumbled down latency, TDL) and the number of errors (NE)
committed for the animals in each beam. The width of the beam was
2.5 cm and the shape was rectangular.
2.5. Mitochondria isolation and GSH determination
Mitochondrial fraction was isolated from liver and brain by Percoll
density gradient centrifugation as described previously [20–22].
Mitochondrial enrichment and integrity were ascertained by the
speciﬁc activity of succinic dehydrogenase and by the acceptor control
ratio determined as the ADP-stimulated oxygen consumption over its
absence using a Clark oxygen electrode with glutamate/malate or
succinate as substrates for respiratory sites for complexes I or II.
Final mitochondrial fraction was devoid of contamination by ER,
plasma membrane, recycling endosomes and lysosomes as assessed
by the levels of Bip/GRP78, Na+/K+ ATPase a1, Rab11 and acid
phosphatase levels, respectively. Alternatively, primary mouse hepato-
cytes and ﬁbroblasts were fractionated into cytosol and mitochondria
by digitonin permeabilization as described previously [23]. In some
cases, for the determination of mGSH levels the isolation buﬀer
(250 mM sucrose, 20 mM HEPES, 1 mM EDTA, 1 mM EGTA, 1.0%
(w/v) BSA, 25microl/100 mL protease inhibitor mixture, pH7.4) was
supplemented with 1 mM DTT as described [24]. GSH levels in
homogenates and mitochondrial fraction were determined by HPLC
as described [21].
2.6. Lipidomic sphingolipid analysis
Mass spectrometry analysis of lipid species was performed in liver
and brain samples from Npc1-/- mice with or without GSH-EE
treatment. Tissue homogenates were pelleted, washed in PBS, and
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Fig. 1. Eﬀect of GSH-EE or NAC therapy on GSH homeostasis in NPC disease. Npc1-/- mice were treated with saline (vehicle), GSHEE or NAC at postnatal day 7 every 12 h
for 6 weeks to isolate mitochondria from liver and brain. (A) GSH levels in mitochondria from liver and (B) GSH levels in mitochondria from brain. Values are compared to liver and
brain mitochondria from Npc1+/+ mice. Data are presented as means ± SEM (n=3 to 11, P < 0.05, two-way ANOVA and Tukey's Multiple Comparison Post-test). (C) GSH levels in
mitochondria from ﬁbroblasts from control subjects (NPC+/+) or NPC patients (NPC-/-) incubated in vitro with GSH-EE (5 mM) or NAC (10 mM). Data are presented as means ± SEM
(n=3 to 6, P < 0.05, two-way ANOVA and Tukey's Multiple Comparison Post-test). (D) Mitochondrial GSH in hepatocytes from Npc1+/+ mice and Npc1-/- mice treated or not with
GSH-EE or NAC as in (A). Data are presented as means ± SEM (n=3, P < 0.05, two-way ANOVA and Tukey's Multiple Comparison Post-test). Total GSH levels from liver (E) or brain (F)
homogenates of Npc1+/+ mice and Npc1-/- mice treated with saline (vehicle), GSHEE or NAC. Data are presented as means ± SEM (n=5–7, P < 0.05, two-way ANOVA and Tukey's
Multiple Comparison Post-test). Total GSH levels of homogenates from hepatocytes from Npc1+/+ mice and Npc1-/- mice (G) or ﬁbroblasts from control subjects or NPC patients (H)
treated with GSH-EE, NAC or saline. Data are means ± SEM (n=5–7, P < 0.05, two-way ANOVA and Tukey's Multiple Comparison Post-test).
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transferred to glass vials. Sphingolipid extracts, spiked with internal
standards (N-dodecanoylsphingosine, N-dodecanoylglucosylsphingo-
sine, N-dodecanoylsphingosylphosphorylcholine and C17-dihydro-
sphingosine, 0.2 nmol each), were prepared as described [25]. The
instrument consisting of a Waters Aquity UPLC system connected to a
Waters LCT Premier orthogonal accelerated time of ﬂight mass
spectrometer (Waters, Millford, MA), operated in positive electrospray
ionisation mode. Full scan spectra from 50 to 1500 Da were acquired
and individual spectra were summed to produce data points each 0.2 s.
Mass accuracy and reproducibility were maintained by using an
independent reference spray by the LockSpray interference. The
analytical column was a 100 mm x 2.1 mm i.d., 1.7 µm C8 Acquity
UPLC BEH (Waters). The two mobile phases were phase A: water/
formic acid (500/1 v/v); phase B: methanol/formic acid (500/1 v/v),
both also contained 5 mM ammonium formate. A linear gradient was
programmed— 0.0 min: 80% B; 3 min: 90% B; 6 min: 90% B; 15 min:
99% B; 18 min: 99% B; 20 min: 80% B. The ﬂow rate was 0.3 mL/min.
The column was maintained at 30 °C. Quantiﬁcation was carried out
using the extracted ion chromatogram of each compound, using
50mDa windows. The linear dynamic range was determined by
injecting standard mixtures.
2.7. Tissue and ﬁbroblasts respirometry
Fresh liver and cerebellum samples from Npc1+/+, Npc1-/- and
Npc1-/- mice treated with GSH-EE were homogenized mechanically
with a PBI Schredder System (Pressure Biosciences, South Easton, MA,
USA) [26] in MiR05 respiratory media (sucrose, 110 mM; potassium
lactobionate, 60 mM; EGTA, 0.5 mM; MgCl2·6H2O, 3 mM; taurine,
20 mM; KH2PO4, 10 mM; HEPES, 20 mM; BSA, 1 g/L; pH 7.1 at
37 °C). Homogenates were introduced in the 2 mL chamber of an
Oroboros-2k™ respirometer (Oroboros® Instruments GmbH Corp,
Austria) to perform high-resolution respirometry studies. To assess
mitochondrial respiration through complex I (CI) malate (2 mM),
pyruvate (5 mM) and glutamate (10 mM) were added (leak state)
subsequently ADP+MgCl2 (5 mM) and cytochrome c (10 mM) were
titrated (coupled CI). Cytochrome c was added to assess the integrity of
the membrane to rule out damage (permeabilization) of the outer
mitochondrial membrane during sample preparation. To study com-
plex II (CII), rotenone (0.5 mM) was added to inhibit CI before the
addition of succinate (10 mM). To study uncoupled CII, oligomycin
(2.5uM) was added to inhibit ATP synthase (or complex V, CV).
Coupled CII respiration was calculated by substracting the uncoupled
CII respiration from the CII respiration. To study the electron transport
system capacity (ETS), subsequently the protonophore carbonyl cya-
nide-4-(triﬂuoromethoxy) phenylhydrazone (FCCP) was added in
followed titrations until reaching the maximal respiration. Finally
antimycin A, a complex III inhibitor, was added to inhibit respiration.
The residual oxygen consumption remaining after antimycin A addition
was substracted from all previous respiratory states. Protein levels were
measured in the liver and cerebellum homogenates for the normal-
ization of the diﬀerent respiratory states.
Fibroblast from control subjects and patients with NPC disease
were culture to determine Routine (R) respiration. To study uncoupled
respiration, oligomycin was added to inhibit ATP synthase. Coupled
respiration was calculated by substracting the uncoupled respiration
from the routine respiration. To study ETS capacity, FCCP was titrated
until reaching maximal respiration. In this case, oxygen consumption
values were normalized by number of cells.
2.8. Statistical analyses
Statistical analyses were performed using GraphPad Prism 6
(Graphpad Software Inc). Unpaired Student’s t-test (two tailed) was
performed between two groups and one or two-way ANOVA followed
by Tukey’s Multiple Comparison test were used for statistical compar-
isons between three or more groups. Kaplan-Meier survival curves
were plotted using the GraphPad Prism and the log-rank test was
undertaken to determine the statistical signiﬁcance. The corresponding
number of experiments is indicated in the ﬁgure legends. Data in
graphs are shown as mean ± s.e.m.
3. Results
3.1. GSH-EE treatment but not NAC restores mGSH levels in liver
and brain from Npc1-/- mice and ﬁbroblasts from NPC patients
Besides endolysosomes, cholesterol has been shown to accumulate
in hepatic and brain mitochondria of Npc1-/- mice [10,14,15].
Consistent with the impairment of mitochondrial GSH transport by
cholesterol [15–17,27], liver and brain mitochondria from Npc1-/-
mice exhibited decreased mGSH levels compared to Npc1+/+ mice
(Fig. 1A, B). Similar ﬁndings were observed in mitochondria from
ﬁbroblasts of NPC patients (Fig. 1C), which also exhibit increased
mitochondrial cholesterol loading [9]. To address the potential impact
of mGSH depletion in NPC disease, we ﬁrst examined strategies to
recover mGSH levels. The pool of mGSH derives from the transport of
cytosolic GSH into the mitochondrial matrix [17,28]. Although NAC
provides cysteine, the rate-limiting amino acid needed for GSH
neosynthesis in the cytosol, mitochondrial cholesterol accumulation
impairs the transport of the newly synthesized cytosolic GSH into
mitochondria due to the cholesterol-dependent decrease of mitochon-
drial membrane ﬂuidity, as reported in steatohepatitis, anthrax infec-
tion and Alzheimer’s disease [14,16,27,29–32]. GSH ethyl ester (GSH-
EE), on the other hand, freely crosses membrane bilayers and diﬀuses
into mitochondria resulting in mGSH replenishment. Indeed, GSH-EE
has been shown to increase mGSH levels in cerebral cortex from
newborn rats [33] and to protect against TNF-induced hepatocellular
apoptosis and diet-mediated steatohepatitis [16,17,32]. Therefore, we
examined the eﬀect of in vivo treatment of Npc1-/-mice with GSH-EE.
As seen, intraperitoneal (i.p.) treatment of Npc1-/- mice at postnatal
day 7 (P7) every 12 h with GSH-EE restored mGSH levels in liver and
brain mitochondria (Fig. 1A, B) as well as in isolated hepatocytes from
Npc1-/- mice (Fig. 1D). Similar replenishment of mGSH by GSH-EE
was observed in ﬁbroblasts from patients with NPC disease (Fig. 1C).
In line with these ﬁndings, GSH-EE increased total GSH levels in
Npc1-/- mice as well as in ﬁbroblasts of NPC patients (Fig. 1E-H). In
contrast, in vivo treatment with NAC at p7 failed to replenish mGSH
stores in aﬀected organs of Npc1-/- mice or ﬁbroblasts from NPC
patients (Fig. 1A-D), although it eﬃciently increased total GSH levels,
in agreement with previous ﬁndings [7]. GSH-EE treatment, however,
did not prevent the accumulation of cholesterol in mitochondria
isolated from liver and brain from Npc1-/- mice (21 ± 3 vs 25 ± 4 μg
cholesterol/mg protein in liver mitochondria from Npc1-/- and
Npc1-/-+GSH-EE groups, respectively, and 35 ± 6 vs 32 ± 5 μg choles-
terol/mg protein in brain mitochondria from Npc1-/- and
Npc1-/-+GSH-EE groups, respectively), suggesting that the recovery
of mGSH by GSH-EE is independent of cholesterol-mediated impair-
ment in the transport of GSH into mitochondria. These ﬁndings show
that unlike NAC, GSH-EE is capable of restoring mGSH pool in
Npc1-/- mice and in ﬁbroblasts from NPC patients.
3.2. Intraperitoneal GSH-EE therapy improves NPC pathology and
extends the survival of Npc1-/- mice
Premature death is a characteristic feature of NPC disease, and
hence we next examined the survival of Npc1-/- mice following GSH-
EE and NAC treatment in vivo. Although somewhat lower than
reported in some studies [34,35], the median survival and maximal
life span of our vehicle-treated Npc1-/- colony were in line with
previous reports [19,36,37]. As seen, intraperitoneal GSH-EE therapy
signiﬁcantly extended the median survival and increased the maximum
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Fig. 2. Intraperitoneal treatment with GSH-EE improves NPC pathology and extends survival of Npc1-/- mice. (A) Kaplan-Meier survival plots and medium survival of
Npc1-/- mice treated with GSH-EE, NAC or saline (vehicle) at P7 every 12 h. P < 0.0002 vs. Npc1-/- mice treated with NAC or vehicle. (B) Eﬀect of GSH-EE or NAC therapy in body
weight gain of Npc1-/-mice. Mice were treated as in (A) and body weight was recorded weekly until demise. (C) Hanging test and (D) beam transversal test in Npc1-/-mice treated with
vehicle or GSH-EE at p7 every 12 h for 6 weeks. Data are presented as means ± SEM (n=7 to 13, P < 0.05 vs. Npc1+/+ mice or Npc1-/- mice, one-way ANOVA and Tukey's Multiple
Comparison Post-test). (E) Calbindin immunostaining in cerebellar paraﬃned sections of Npc1+/+mice and Npc1-/-mice following treatment with saline (vehicle) or GSH-EE. Images
are representative of 5 replicates showing similar results. (F-H) Liver sections from Npc1+/+ mice and Npc1-/- mice treated with saline or GSH-EE analyzed by H&E. Representative
images of 6 replicates are shown. (I, J) Serum ALT levels from Npc1+/+mice and Npc1-/-mice treated with saline or GSH-EE. Data are presented as means ± SEM (n=7 to 14, P < 0.05
vs. Npc1+/+ mice or Npc1-/- mice, one-way ANOVA and Tukey's Multiple Comparison Post-test).
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life span of Npc1-/- mice with respect to vehicle-treated Npc1-/- mice
(Fig. 2A), similar to the eﬀect we observed following subcutaneous
treatment of Npc1-/- mice with 2-hydroxypropyl-β-cyclodextrin
(CDX), an agent that extracts cholesterol from membrane bilayers
[34], or CDX plus GSH-EE (Torres et al, mansucript in preparation).
Moreover, GSH-EE-treated Npc1-/- mice maintained a signiﬁcantly
higher body weight compared to vehicle-treated Npc1-/- mice, while
Npc1-/- mice treated with NAC exhibited somewhat lower body weight
gain (Fig. 2B). Consistent with the inability of NAC to replenish mGSH
levels, intraperitoneal NAC therapy did not have a signiﬁcant impact in
the survival of Npc1-/- mice (Fig. 2A), in agreement with previous
observations [7].
As NPC disease causes neurodegeneration, with characteristic signs
of cerebellar ataxia, and liver disease, we next addressed the patholo-
gical impact of mGSH replenishment by GSH-EE. GSH-EE treatment
improved motor coordination assessed by the hanging and beam
transversal tests (Fig. 2C, D). Consistent with this outcome, the levels
of calbindin, a calcium-binding protein critical for the precision of
motor coordination [38], were reduced in cerebellar Purkinje cells from
Npc1-/- mice while GSH-EE treatment signiﬁcantly increased calbin-
din expression (Fig. 2E). Moreover, Npc1-/- mice exhibited age-
dependent liver injury assessed by serum ALT levels that was evident
7 weeks after birth (Supplementary Fig. 1). H &E analyses indicated
alterations in liver parenchyma with the presence of inﬂammatory foci,
bigger and more irregular hepatocytes with foamy cytoplasm, suggest-
ing lipid accumulation (Fig. 2F). In addition, compared to vehicle-
treated Npc1-/- mice GSH-EE therapy at P7 signiﬁcantly decreased
liver damage as indicated by H&E analyses (Fig. 2 G, H) and decreased
levels of serum transaminases (Fig. 2 I, J). Thus, these ﬁndings
underscore that GSH-EE therapy ameliorates NPC pathology and
increases the survival of Npc1-/- mice.
3.3. GSH-EE treatment protects against oxidative stress in Npc1-/-
mice and ﬁbroblasts from patients with NPC disease
Given the lack of therapeutic eﬀect of NAC in the survival of
Npc1-/- mice, we next examined potential mechanisms underlying the
beneﬁcial eﬀect of mGSH replenishment by GSH-EE treatment. As
NPC disease is characterized by oxidative stress [7,11], we ﬁrst
examined the susceptibility to oxidant-induced cell death. As seen,
GSH-EE treatment protected isolated hepatocytes from Npc1-/- mice
and ﬁbroblasts from NPC patients against hydrogen peroxide-induced
cell death (Fig. 3A, B). In line with these ﬁndings, in vivo treatment of
Npc1-/- mice with GSH-EE decreased oxidative stress in liver and
cerebellum as revealed by reduced carbonylated proteins (Fig. 3C, D).
Moreover, GSH-EE administration attenuated the increase of
MitoSOX™ ﬂuorescence in hepatocytes isolated from Npc1-/- mice
(Fig. 3E), indicating reduced generation of superoxide anion, while
GSH-EE treatment increased mitochondrial membrane potential
(Fig. 3F). Furthermore, GSH-EE therapy signiﬁcantly increased ATP
levels in liver and cerebellum from Npc1-/- mice (Supplementary
Fig. 2), suggesting improved energy status. Furthermore, Npc1-/- mice
exhibited increased caspase-3 processing to active fragment in liver
and cerebellum and GSH-EE treatment decreased caspase 3 activity
(Fig. 3G, H). Moreover, increased plasma levels of cholesterol oxidation
products have been identiﬁed as sensitive and speciﬁc markers of NPC
disease [39]. In line with these ﬁndings, we observed increased plasma
levels of the oxysterols cholestane 3β, 5α, 6β-triol and 7-ketocholester-
ol, which were diﬀerentially aﬀected by GSH-EE treatment
(Supplementary Fig. 3). NPC disease most severely aﬀects Purkinje
cells of the cerebellum. As seen, nitrotyrosine immunohistochemical
analysis of cerebellar frozen sections indicated marked nitrotyrosyla-
tion in granule and Purkinje cells from Npc1-/- mice compared to
Npc1+/+ mice (Fig. 3I). Interestingly, GSH-EE treatment reduced
protein nitrotyrosylation in cerebellar slices from Npc1-/- mice
(Fig. 3I). Thus, these ﬁndings indicate that GSH-EE therapy attenuates
the susceptibility to oxidative stress and cell death in NPC disease.
3.4. GSH-EE therapy improves mitochondrial function in cerebellum
from Npc1-/- mice
As mitochondria are one of the main culprits of ROS overgeneration
leading to oxidative stress, we next evaluated the eﬀects of GSH-EE
treatment in mitochondrial function and morphology. High-resolution
respirometry analyses were performed in homogenates from cerebel-
lum of Npc1-/- mice with or without i.p. GSH-EE treatment. Oxygen
consumption rate assessed at the leak state (no ADP, state 2 respira-
tion) in the presence of malate and glutamate (complex I substrates)
was similar in the cerebellum of Npc1+/+ and Npc1-/- mice and was
not aﬀected upon GSH-EE treatment (Fig. 4A). However, oxidative
phosphorylation through complex I in the presence of ADP was
reduced in cerebellum of Npc1-/- mice, and this eﬀect was recovered
by GSH-EE treatment (Fig. 4A). GSH-EE treatment caused similar
eﬀects when the respiratory capacity was evaluated in the presence of
rotenone (complex I inhibitor) and succinate (complex II substrate)
and with the addition of the ATP synthase inhibitor oligomycin and the
pronotophore FCCP to monitor coupled respiration and the maximal
electron transfer System (ETS), respectively (Fig. 4B). A similar out-
come was observed in liver homogenates of Npc1-/- mice compared to
Npc1+/+ mice, but unlike in cerebellum, GSH-EE treatment failed to
restore leak respiration, oxidative phosphorylation via complex I and II
as well as coupled and ETS respiration via complex II (Supplementary
Fig. 4). Fibroblasts from patients with NPC disease showed a sig-
niﬁcant reduction in mitochondrial performance at routine, coupled
and ETS respiratory states compared to ﬁbroblasts from healthy
subjects (Supplementary Fig. 5). These ﬁndings of mitochondrial
respiratory rates in liver and cerebellum correlate with the expression
of mitochondrial complexes (Fig. 4C). Blue native electrophoresis
revealed signiﬁcant downregulation of supercomplexes I1+III2+IV2
and, particularly, complex IV in liver but not cerebellum of Npc1-/-
mice that was not reversed by GSH-EE treatment, with modest
diﬀerences observed regarding complex CIV levels in cerebellum
(Fig. 4C). Western blot analyses revealed decreased expression of the
mitochondrial DNA (mtDNA)-encoded subunit of the CIV cytochrome
c oxidase I in liver but not cerebellum that was not prevented by GSH-
EE treatment (Supplementary Fig. 6). Moreover, electron microscopy
analyses showed autophagic vacuoles of electron-dense materials,
mitochondrial morphological alterations predominantly in liver with
decreased mitochondrial number and increased length (Supplemental
Fig. 7) without a signiﬁcant eﬀect following GSH-EE treatment. In
contrast to the liver, the mitochondrial structure and number in
cerebellum was similar between Npc1+/+ and Npc1-/- mice and
GSH-EE treatment increased the mitochondrial length in Npc1-/-mice
(Fig. 4D, E). Overall, these ﬁndings point to reversible functional
mitochondrial alterations in cerebellum of Npc1-/- mice, which are
largely restored by GSH-EE treatment, suggesting the involvement of
an oxidative stress-dependent mechanism of mitochondrial dysfunc-
tion. The mitochondrial alteration in liver of Npc1-/- mice likely
reﬂects structural defects with decreased expression of mtDNA-en-
coded subunits and assembly of mitochondrial complexes that are
refractory to GSH-EE administration.
3.5. Eﬀect of GSH-EE therapy in the shingolipidomic proﬁle of liver
and brain from Npc1-/- mice
In addition to cholesterol, NPC disease is also characterized by the
accumulation of sphingolipids in the aﬀected organs [6]. Therefore, we
next addressed whether GSH-EE treatment induced major changes in
the sphingolipidomic proﬁle in liver and brain of Npc1-/- mice. As seen,
mass spectrometry analysis revealed increased levels of speciﬁc mole-
cular species of ceramide, sphingomyelin, monohexosylceramide (glu-
cosyl and galactosylceramides), dihexosylceramide (lactosylceramides)
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Fig. 4. High-resolution respirometry of cerebellum fromNpc1-/- mice treated with GSH-EE. Cerebellar homogenates of Npc1+/+mice or Npc1-/-mice treated with saline
or GSH-EE were analyzed in Oroboros-2k™ respirometer. (A) For mitochondrial respiration through complex I, malate 2 mM, pyruvate 5 mM and glutamate 10 mM were added with or
without ADP+MgCl2 (5 mM) to determine respiration at couple or leak states, respectively. Data are presented as means ± SEM (n=3 to 7, P < 0.05 vs. Npc1
+/+ or Npc1-/- mice, one-way
ANOVA and Tukey's Multiple Comparison Post-test). (B) Oxidative phosphorylation through complex II was determined using succinate (10 mM) as substrate in the presence of
rotenone (0.5 mM). Uncoupled respiration through complex II was determined in the presence of oligomycin (2.5 µM) and the electron transport System capacity was determined in the
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and sphingosine in liver of Npc1-/- mice (Fig. 5). The increase of
sphingolipids in brain of Npc1-/-mice was evident for ceramide C18:0,
dihexosylceramides C18GGCer and C20GGCer and sphingosine
(Fig. 6). In contrast to these ﬁndings, the levels of speciﬁc sphingo-
myelin (C22SM, C24SM, C24:1SM and C24:2SM) and, particularly, the
most predominant monohexosylceramide species (C18GCer, C20GCer,
C22GCer, C24GCer and C24:1GCer) decreased in brain of Npc1-/-
mice compared to Npc1+/+ mice (Fig. 6), in agreement with previous
ﬁndings [6]. These changes in sphingolipid homeostasis were accom-
panied by unchanged expression of glucosylceramide synthase (GCS)
and sphingomyelin synthase (SMS) 2 in liver and brain, while that of
SMS 1 decreased in liver (Fig. 7). Interestingly, the sphingolipidomic
proﬁle of the liver from Npc1-/-mice treated with GSH-EE was similar
to that of vehicle-treated Npc1-/- mice (Fig. 5). Moreover, GSH-EE
treatment did not signiﬁcantly change the proﬁle of ceramide, dihexo-
sides species or sphingosine levels in brain of Npc1-/- mice, except for
the normalization of speciﬁc molecular species of sphingomyelin and
monohexosylceramides in the brain of Npc1-/- mice (Fig. 6). These
ﬁndings underscore that GSH-EE therapy has a modest and selective
eﬀect on the sphingolipid proﬁle in Npc1-/- mice.
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Fig. 5. Mass spectrometry analyses of hepatic sphingolipid proﬁle ofNpc1-/-mice. Liver samples from Npc1+/+mice and Npc1-/-mice treated with saline or GSH-EE at p7
every 12 h for 6 weeks were processed for lipidomic analyses of ceramide (A); sphingomyelin (B); monohexosides (C); dihexosides (D) species and sphingosine (E) levels. Values are the
mean ± SEM of 5 mice per group. P < 0.05 vs. Npc1+/+ or Npc1-/- samples as indicated.
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4. Discussion
The primary biochemical feature of NPC disease is the accumula-
tion of free cholesterol, predominantly in endolysosomes, due to
defective NPC1 function. Also described but poorly characterized is
the increase of cholesterol in mitochondria in the aﬀected organs of
Npc1-/- mice. As mitochondrial cholesterol accumulation depletes the
mGSH pool [14,15], we examined for the ﬁrst time the impact of
mGSH replenishment in NPC disease. Our ﬁndings show a diﬀerential
outcome between NAC and GSH-EE in the compartimentalization of
GSH in NPC disease. Incubation of hepatocytes from Npc1-/-mice and
ﬁbrosblasts of NPC patients with NAC and GSH-EE results in a
signiﬁcant increase in total GSH levels. Moreover, consistent with the
ability to cross the blood brain barrier [14,33], in vivo treatment with
both precursors increased total GSH levels in liver and brain homo-
genates from Npc1-/- mice, in agreement with previous ﬁndings [7].
However, unlike GSH-EE, NAC failed to restore the mGSH pool despite
signiﬁcantly increasing total GSH levels. The inability of NAC to
increase mGSH in NPC disease is in line with ﬁndings in liver and
alveolar type II cells following chronic alcohol drinking [20,23,40],
which causes increased mitochondrial cholesterol loading [41,42] and
subsequent impairment in the transport of GSH from the cytosol into
mitochondria through disruption of membrane dynamics.
Interestingly, we show that the proﬁciency of NAC to restore total
GSH levels but not the mGSH pool had little impact in the survival of
Npc1-/- mice or NPC pathology, in line with previous studies [7,43].
Accordingly, short-term NAC administration to NPC patients revealed
no signiﬁcant eﬀects on oxidative stress [7]. In addition, vitamin C
treatment did not signiﬁcantly modify disease progression nor in-
creased life span of Npc1-/- mice [13]. Thus, while oxidative stress is a
characteristic feature of NPC disease, treatment with antioxidants or
replenishment of total GSH levels is not an eﬃcient approach to modify
disease progression.
The present ﬁndings provide evidence that selective restoration of
mGSH following GSH-EE therapy has a promising therapeutic impact
in NPC disease, signiﬁcantly preserving calbindin levels, improving
motor coordination and increasing the survival of Npc1-/- mice. While
GSH-EE treatment increased mGSH levels in both liver and cerebel-
lum, the normalization of mitochondrial function was only observed in
the latter, which paralleled the improvement of Purkinje cell survival
and protection against oxidative stress, likely mediating the enhanced
motor coordination and increased survival. Recent observations in-
dicated that the hepatic re-expresion of NPC1 in Npc1-/- mice corrects
the liver phenotype of the disease, although, this outcome had no
impact in improving neurological symptoms or life-span extension
[37]. These ﬁndings along with our observations suggest that the
neurological alterations rather than the liver phenotype determine the
overall progression of the juvenile form of the disease. Moreover, our
ﬁndings indicate that GSH-EE treatment does not aﬀect the lipidomic
proﬁle of most sphingolipid species in liver and brain of Npc1-/- mice,
except for speciﬁc sphingomyelin and monohexosylceramide species in
brain of Npc1-/- mice. However, the relevance of the latter ﬁndings
remains to be further investigated, as the role of the disruption of
sphingolipid homeostasis in NPC disease is poorly understood. For
instance, although accumulation of gangliosides, especially GM2 and
GM3, has been reported in brain of Npc1-/- mice [6], GM3 synthase
deletion has been shown to worsen NPC disease resulting in acceler-
ated premature death of Npc1-/- mice despite decreasing GM3 levels
[44]. In light of these ﬁndings, it seems unlikely that the eﬀect of GSH-
EE in the normalization of speciﬁc brain sphingolipid species may have
contributed to the improvement in the neurological phenotype and
increased survival of Npc1-/- mice.
Currently, there are no FDA-approved treatments for NPC disease.
Given the promising eﬀects of GSH-EE shown here and exploiting the
fact that it crosses the blood brain barrier, it may be worth exploring its
clinical use alone or in combination with other therapies that have
shown beneﬁcial eﬀects in NPC pathology, including curcumin, which
signiﬁcantly attenuated NPC pathology and extended survival by 30%
Fig. 6. Sphingolipidomic proﬁle of brain of NPC1-/- mice. Brain samples from Npc1+/+ mice and Npc1-/- mice treated with saline or GSH-EE at p7 every 12 h for 6 weeks were
processed for mass spectrometry analyses of ceramide (A); sphingomyelin (B); monohexosides (C); dihexosides (D) species and sphingosine (E) levels. Values are the mean ± SEM of 5
mice per group. P < 0.05 vs. Npc1+/+ or Npc1-/- samples as indicated.
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in Npc1-/- mice by restoring intracellular sphingosine unbalance and
cytosolic calcium homeostasis [36], ibuprofen [13], chronic adminis-
tration of HDAC inhibitors [45], or miglustat [6,35], which inhibits
GCS and has been approved in Europe for the treatment of NPC
patients. Of note, miglustat or Genz-529468, a more eﬀective GCS
inhibitor, have been shown to signiﬁcantly delay motor impairment
and premature death in Npc1-/- mice despite increased brain gluco-
sylceramide levels [35], suggesting these inhibitors have oﬀ-target
eﬀects likely targeting the non-lysosomal glucosylceramidase.
Moreover, although cholesterol-lowering approaches such as choles-
tyramine, statins and a low-cholesterol diet are ineﬀective in modifying
the neurological progression of the disease [46,47], CDX, a cholesterol-
extracting agent, exhibits promising eﬀects in ameliorating NPC
pathology. CDX contains a hydrophilic exterior and a hydrophobic
interior allowing it to increase the solubility of poorly water-soluble
molecules such as cholesterol. CDX has been reported to remove
cholesterol from cultured cells [48,49], while intraperitoneal or sub-
cutaneous CDX administration to Npc1-/- mice decreased free choles-
terol storage in liver and delayed the onset of neurological disease,
increased Purkinje cell survival and extended life span [34,50].
However, as CDX does not readily cross the blood brain barrier [51],
the therapeutic eﬃcacy of intraperitoneal or subcutaneous CDX
administration in ameliorating NPC symptoms is puzzling. Therefore,
since recent ﬁndings indicated that the intracisternal CDX administra-
tion prevents cerebellar dysfunction and delays premature death in
feline NPC disease [52], it may be worth investigating whether GSH-EE
combined with intrathecal injection of CDX via lumbar puncture may
exhibit a potentiating eﬀect in the treatment of NPC disease. Although
to our knowledge there are no studies addressing the suitability of
GSH-EE treatment for human therapy, the present ﬁndings suggest
this approach may be worth exploring in patients with NPC disease.
In summary, the present ﬁndings provide new insights on the
pathogenesis of this lysosomal storage disorder, with the identiﬁcation
of mGSH depletion as an important player. In addition, since mito-
chondrial cholesterol increase causes the depletion of mGSH, further
understanding the mechanism underlying the accumulation of choles-
terol in mitochondria may be of relevance in NPC disease. In this
regard, we have observed increased expression of StARD1 levels in liver
and brain of Npc1-/- mice by an ER stress-independent mechanism,
and this outcome is accompanied by a signiﬁcant upregulation of
MLN64 (Torres et al, manuscript in preparation). Given the known
functions of these proteins in intracellular cholesterol traﬃcking
[53,54], these ﬁndings suggest that StARD1 and MLN64 could account
for the accumulation of cholesterol in mitochondria and the expected
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